ECs in Canada
This article was originally published in The Tan Sheet
Executive Summary
Women's Capital Corp.'s progestin-only morning-after pill, Plan B, could be available "behind-the-counter" in Canada within a year, group says. WCC submitted an application to Health Canada March 6 to switch the EC from prescription-only to nonprescription status; if approved, Plan B would be dispensed by trained pharmacists operating under a protocol developed by the Canadian Pharmacists Association and Society of Obstetricians & Gynecologists of Canada. Application includes results from a label comprehension study of 600 American women, as well as post-marketing safety data from Europe. WCC also is in final stages of an actual-use study involving 600 women in Washington; once it is complete, the group will have enough information to submit an application to FDA, which it plans for late summer...
You may also be interested in...
Canadian Plan B Pharmacy Status Proposal Will Not Address Age Restriction
Discussion of an age restriction for purchase of Barr Labs' Plan B (levonorgestrel) will not be included in the Canadian government's evaluation of a potential switch to behind-the-counter status for the emergency contraceptive
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.